Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Lianyungang Jinkang Hexin Pharmaceutical Co. Ltd. is active in the Biotechnology & Pharmaceuticals technology area. The company currently has 2 pending office actions. These actions are distributed across 2 distinct examiners and 2 distinct art units. Rehana Ismail is the busiest examiner, managing 1 pending office action.
The 2 pending office actions are split between 2 distinct examiners. The involvement of 2 distinct art units indicates that the company's pharmaceutical filings are being reviewed by different specialized groups. Rehana Ismail's single pending action represents 1 of the 2 current matters.
Practitioners must navigate the specific expectations of both Rehana Ismail and the other examiner across their respective 2 distinct art units. The Biotechnology & Pharmaceuticals focus requires precise technical arguments tailored to each department. Successfully managing these 2 pending office actions involves coordinating responses that satisfy the unique requirements of both Rehana Ismail and the broader 2 distinct art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ISMAIL, REHANA | 1 | 76.2% | +34.8% |
| CORNET, JEAN P | 1 | 41.9% | +47.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18574162 | USE OF FOLATE DERIVATIVE IN PREPARATION OF DRUG FOR TREATING CONTACT LENS DISCOMFORT AND DRY EYE | ISMAIL, REHANA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17639993 | USE OF 5-METHYLTETRAHYDROFOLATE | CORNET, JEAN P | 34d |
| 18574162 | USE OF FOLATE DERIVATIVE IN PREPARATION OF DRUG FOR TREATING CONTACT LENS DISCOMFORT AND DRY EYE | ISMAIL, REHANA | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18574162 | USE OF FOLATE DERIVATIVE IN PREPARATION OF DRUG FOR TREATING CONTACT LENS DISCOMFORT AND DRY EYE | ISMAIL, REHANA | 1625 | §102§103§112 | Non-Final OA | — | Pending | Dec 26, 2023 |
| 17639993 | USE OF 5-METHYLTETRAHYDROFOLATE | CORNET, JEAN P | 1628 | §102 | Non-Final OA | 34d | Pending | Mar 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLianyungang Jinkang Hexin Pharmaceutical Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Rehana Ismail has the most, with 1 of Lianyungang Jinkang Hexin Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
